ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey
April 17, 2023 08:03 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich and Princeton, NJ, April 17, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company has opened its U.S....
ITM lädt zu Symposium und Messestand auf der Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig ein
April 14, 2023 05:48 ET
|
ITM Isotope Technologies Munich SE
Garching / München, 14. April 2023 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Biotech-Unternehmen, nimmt an der 61. Jahrestagung der Deutschen Gesellschaft für...
ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference
March 16, 2023 09:48 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company will present an overview of genetic...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
March 13, 2023 06:13 ET
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 10:30 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will...
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
October 27, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has...
ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177
October 24, 2022 02:30 ET
|
ITM Isotope Technologies Munich SE
ONTARIO, CANADA, and MUNICH, GERMANY, October 24, 2022 – An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM),...
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
October 19, 2022 08:00 ET
|
ITM Isotope Technologies Munich SE
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patients Garching/Munich, Germany, October 19, 2022 – ITM...
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
October 13, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production...
ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network
September 08, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, and Grand Rapids, MI, U.S., September 08, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and BAMF (Bold Advanced Medical...